Overview

A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This multicenter, non-randomized, open-label, single- and multiple-ascending-dose study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6867461 in patients with wet age-related macular degeneration.
Phase:
Phase 1
Details
Lead Sponsor:
Hoffmann-La Roche